Pelthos Therapeutics to Present at 38th Annual ROTH Conference
Globenewswire·2026-03-12 12:30
Company Overview - Pelthos Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapeutic products for unmet patient needs [3] - The company's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, is the first and only prescription therapy approved for home use to treat Molluscum contagiosum [3] - Pelthos also offers Xepi® (ozenoxacin) Cream, 1%, for impetigo, and Xeglyze® (abametapir) for head lice [3] Upcoming Events - CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026, at 3:00 p.m. Pacific Time [1] - A live webcast of the fireside chat will be available on the company's website, with a replay accessible for 90 days post-event [2]